Efficacy of platinum-based doublet chemotherapy versus single-agent chemotherapy as second-line treatment in elderly patients with advanced non-small cell lung cancer
10.3760/cma.j.issn.0254-9026.2019.03.005
- VernacularTitle:老年晚期非小细胞肺癌患者二线铂类联合方案和单药方案疗效的对比研究
- Author:
Xiangtao YAN
1
;
Huijuan WANG
;
Peng LI
;
Guowei ZHANG
;
Mina ZHANG
;
Jinpo YANG
;
Zhiyong MA
Author Information
1. 郑州大学附属肿瘤医院河南省肿瘤医院内科
- Keywords:
Carcinoma;
non-small-cell lung;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Geriatrics
2019;38(3):242-245
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and tolerance of platinum-based doublet chemotherapy versus single-agent chemotherapy as second-line treatment in elderly patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 85 elderly patients with advanced NSCLC after first-line treatment were retrospectively analyzed and divided into the combination therapy group(n=40,taking platinum-based doublet chemotherapy)and the single-agent chemotherapy group(n=45,receiving single-agent second-line chemotherapy).Results There were no significant differences in the objective response rate (ORR)and the disease control rate (DCR)between the combination therapy group and the single-agent chemotherapy group(27.5 ％ or 11/40 vs.20.0 ％ or 9/45,60.0％ or 24/40 vs.73.3％ or 33/45,x2 =0.662 and 1.704,P=0.416 and 0.192).The median progression-free survival(PFS)was 3.8 months for the combination therapy group and 2.8 months for the single-agent chemotherapy group(P =0.045).The rate of grade Ⅲ/Ⅳ hematological toxicity was higher in the combination therapy group than in the single-agent chemotherapy group.Conclusions Platinum-based doublet chemotherapy has longer PFS than the single-agent chemotherapy as secondline treatment in elderly patients with advanced non-small cell lung cancer,and more attention should be paid to its high hematological toxicity.
